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Influenza A virus (IAV) is a major cause of morbidity andmortality throughout the world. Current antiviral therapies include
oseltamivir, a neuraminidase inhibitor that prevents the release of nascent viral particles from infected cells. However, the IAV
genome can evolve rapidly, and oseltamivir resistance mutations have been detected in numerous clinical samples. Using an in
vitro evolution platform and whole-genome population sequencing, we investigated the population genomics of IAV during the
development of oseltamivir resistance. Strain A/Brisbane/59/2007 (H1N1) was grown inMadin-Darby canine kidney cells with
or without escalating concentrations of oseltamivir over serial passages. Following drug treatment, the H274Y resistance muta-
tion fixed reproducibly within the population. The presence of the H274Ymutation in the viral population, at either a low or a
high frequency, led to measurable changes in the neuraminidase inhibition assay. Surprisingly, fixation of the resistance muta-
tion was not accompanied by alterations of viral population diversity or differentiation, and oseltamivir did not alter the selec-
tive environment. While the neighboring K248Emutation was also a target of positive selection prior to H274Y fixation, H274Y
was the primary beneficial mutation in the population. In addition, once evolved, the H274Ymutation persisted after the with-
drawal of the drug, even when not fixed in viral populations. We conclude that only selection of H274Y is required for oseltami-
vir resistance and that H274Y is not deleterious in the absence of the drug. These collective results could offer an explanation for
the recent reproducible rise in oseltamivir resistance in seasonal H1N1 IAV strains in humans.
Influenza A virus (IAV) is a pathogen of primary importance forpublic health. The unique evolutionary mechanisms of IAV, in-
cluding its high mutation rate, segment reassortment, and shifts
betweenmultiple host species, pose significant challenges for con-
trolling disease and developing vaccination and treatment strate-
gies. Therefore, a detailed understanding of influenza virus ge-
nome sequence evolution is imperative. The influenza virion
consists of eight negative-strand RNA segments, which form pro-
tein-RNA complexes enveloped in a lipid membrane (1). The
eight segments encode at least 10 proteins known to be essential
for infectivity and replication. Within a given influenza virus
strain, sequence evolution proceeds by mutation, selection, and
genetic drift, all of which are affected by the environment, the
host, and drug treatment. High mutation rates, together with the
rapid development of influenza epidemics, make tracing the evo-
lutionary history of the virus and discovering the principles gov-
erning IAV’s evolution complex.
Neuraminidase (NA) inhibitors, especially the orally bioavail-
able drug oseltamivir, have been widely used for the treatment of
IAV. These drugs bind to the influenza virus neuraminidase active
site as competitive inhibitors.One great challenge in the treatment
of influenza with NA inhibitors is the development of drug-resis-
tant mutants. Several resistance mutations occur in response to
oseltamivir treatment, including His274Tyr (H274Y), which is
caused by a single nucleotide change and is specific to viruses with
neuraminidase N1 (2, 3). (Nucleotide positions are given accord-
ing to the N2 numbering system.) H274Y-associated oseltamivir
resistance emerged rapidly and spread globally in H1N1 strains
during the 2007-2008 and 2008-2009 influenza seasons (4, 5). The
H274Y mutation is close to the active site of neuraminidase, and
crystal structures reveal the molecular basis of resistance (6). In
addition, N2 viruses have specific neuraminidase mutations, in-
cluding Arg292Lys (R292K) and Glu119Val (E119V), while
Asn294Ser (N294S)mutants have been found amongbothN1 and
N2 viruses (7, 8).
While IAV can develop drug resistance with a single mutation,
how the development of resistance affects IAV population diver-
sity and structure remains unclear. The recurrent selection of ben-
eficial mutations is expected to eliminate variation in the region
surrounding the selected loci (9) as well as to cause increased
divergence between isolated populations (10). Thus, the develop-
ment of drug resistance would be expected to alter the diversity of
IAV populations and to increase divergence between drug-sensi-
tive and drug-resistant populations. For segmented viruses, it has
not been established whether such effects would be limited to
segment 6 (neuraminidase), the target of selection during the de-
velopment of oseltamivir resistance, or would be observed across
the entire genome. Similarly, the presence of drug may alter the
selective landscape by affecting the fitness ofmutations in the drug
or no-drug environment due tomechanisms such as altered struc-
tural constraint or epistatic interactions. Again, the genomewide
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effects of this alteration are unknown. Better knowledge of these
phenomena will yield insights into the evolutionary obstacles and
costs associated with the development of drug resistance and may
aid in future drug design efforts.
The availability of high-throughput sequencing technology en-
ables observation beyond the consensus sequence of the virus and
establishes the genetic structure and low-frequency single nucle-
otide polymorphisms (SNPs) of the viral population. Populations
of RNA viruses such as IAV are likely not genetically uniform but
instead form quasispecies, resulting in a degree of sequence diver-
sity (11). The magnitude of sequence variance within a single IAV
strain and the temporal patterns of evolution are key aspects of
IAV biology and are paramount for predicting viral evolution, re-
sponse to treatment, anddrug resistance.Until now, the evolutionary
trajectories leading to drug resistance in IAV have not been compre-
hensively elucidated. In this study, we combine serial passaging with
high-throughput sequencing to explicitly trace in vitro evolutionary
trajectories of the genome of influenza virus A/Brisbane/59/2007
(H1N1)populations inMadin-Darbycaninekidney(MDCK)cells in
the presence of escalating concentrations of oseltamivir. Population
genetics analysis reveals the fine-scale changes associated with the
presence of oseltamivir and suggests that few evolutionary obstacles
prevent the development of oseltamivir resistance.
MATERIALS AND METHODS
Cells, virus stocks, and chemicals. MDCK cells were obtained from the
American Type Culture Collection (Manassas, VA) and were propagated
in Eagle’s minimal essential medium (EMEM) with 10% fetal bovine se-
rum (FBS; HyClone, Logan, UT) and 2 mM penicillin-streptomycin. In-
fluenza virus A/Brisbane/59/2007 (H1N1), grown in chicken egg allantoic
fluid, was obtained through the NIH Biodefense and Emerging Infections
Research Resources Repository, NIAID, NIH (NR-12282; lot 58550257).
Oseltamivir carboxylate (RO0640802-002; lot 91ST1126/1) was obtained
from F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Determination of viral titers by plaque assay. Viruses were quanti-
fied on MDCK cells to determine infectious titers (expressed in PFU per
milliliter) as described previously (12). In brief, six 10-fold serial dilutions
were performedon the viral samples, followed by 1 hof binding at 37°Con
confluent MDCK cells in 12-well plates. After unbound virus was washed
off with phosphate-buffered saline (PBS), the cells were overlaid with agar
(0.5%) in Dulbecco’s modified Eagle medium (DMEM)–F-12 medium
supplemented with penicillin-streptomycin, L-glutamine, bovine serum
albumin, HEPES, sodium bicarbonate, and 20 g/ml acetylated trypsin
(Sigma, St. Louis,MO). After the agar solidified, the plates were incubated
for48 h at 37°C. Cells were fixed and stained with an anti-H1 primary
antibody (MAB8261; Millipore, Billerica, MA). Plaques were visualized
with a horseradish peroxidase-conjugated anti-mouse secondary anti-
body (BD Biosciences, San Jose, CA) and were developed with a peroxi-
dase substrate kit (Vector Laboratories, Burlingame, CA).
Determination of oseltamivir ED50. The 50% effective dose (ED50)
was defined as the concentration of drug reducing the number of plaques
to 50% of that for the no-drug control. In brief, the ED50 was determined
by seeding 2.5  105 MDCK cells in each well of a 24-well plate and
incubating overnight at 37°C under 5%CO2. Virus was added to cells at a
multiplicity of infection (MOI) of 0.01 in 100l of influenza virus growth
medium (EMEM–10% FBS with 2 mM penicillin-streptomycin, 7.5%
bovine serum albumin, and 1 g/ml tosylsulfonyl phenylalanyl chlorom-
ethyl ketone [TPCK]-treated-trypsin [Sigma]) plus oseltamivir (0, 0.001,
0.01, 0.1, 1, 10, or 100 M). After incubation at 37°C for 1 h, cells were
washed once with PBS; 500l of influenza virus growthmediumwith the
appropriate concentration of oseltamivir was added; and cells were again
incubated at 37°C for several days. Supernatants were collected when
90% cytopathic effect (CPE) was achieved for at least one drug concen-
tration. Supernatants were centrifuged for 15 min at 300 relative centrif-
ugal force (RCF) at 4°C and were stored at80°C. The viral titer for each
sample was determined by plaque assay. The ED50 was the concentration
of oseltamivir yielding a titer of 50% of that without drug.
Determination of oseltamivir IC50.The 50%enzyme-inhibitory con-
centration (IC50) of oseltamivir against IAV was determined by using a
chemiluminescent neuraminidase activity inhibition (NI) assay, com-
mercially available as theNA-Star InfluenzaNeuraminidase Inhibitor Re-
sistanceDetection kit (Applied Biosystems, Foster City, CA), according to
themanufacturer’s instructions. The valueswere determined fromadose-
response curve.
Viral culture.Viruses were serially passaged inMDCK cells (2.5 105
cells per well). The MOI for the initial infection was 0.01. Multiple serial
10-fold dilutions of virus in supernatants were used to select virus for
subsequent passages. Supernatants containing virus were harvested as the
culture reached50% CPE, and the cell-free virus was used for process-
ing for high-throughput sequencing, quantification by plaque assay, and
generation of the next passage. ThemeanMOI for additional passages was
later determined to be 0.04 (range, 0.00001 to 0.1). Trajectories compris-
ing at least 10 serial passages were prepared both in the presence and in the
absence of escalating doses of oseltamivir. In the first passage with oselta-
mivir, the drug concentration was 1 the ED50. For the next passage, the
concentration was increased to 4 the ED50, and it was then doubled for
each subsequent passage as long as50%CPEwas present. If50%CPE
was present, the dose of oseltamivir was escalated at a lower rate. For select
passages, oseltamivir was deliberately withdrawn.
High-throughput sequencing. We developed a high-throughput
sample processing work flow, carried out in a 96-well format, including
RNA purification, reverse transcription, and whole-genome PCR, fol-
lowed by DNA bar coding and library preparation. Samples were purified
using the RNeasy 96 kit (Qiagen, Gaithersburg, MD). Reverse transcrip-
tion was performed with SuperScript III First-Strand Synthesis Supermix
(Life Technologies, Grand Island, NY) by using the recommended proto-
col and IAV universal primers described previously (13). A universal,
multiplex PCR was developed that produces full-length products of the
entire IAV genome in a single reaction. The primers, described by Hoff-
mann et al. (14), were combined in a ratio that provided near-even se-
quence coverage across all segments. The amplification was performed
using PfuUltra II HotStart high-fidelity polymerase (Agilent, Santa Clara,
CA) with the following cycles: 95°C for 2 min; 32 cycles of 95°C for 15 s,
62°C for 15 s, and 72°C for 2.5 min; and finally 72°C for 10 min. Ampli-
fication products were prepared for Illumina sequencing using the Min-
Elute 96 UF PCR purification kit (Qiagen) with the recommended proto-
col. For all subsequent steps, the same purification kit, with reagents from
New England BioLabs (Ipswich, MA), was used between enzymatic reac-
tions, except where otherwise noted. The amplified DNA was sheared
using Fragmentase to produce fragments of 300 to 600 bp. The sheared
DNA was repaired with the Blunt Enzyme Mix and was A tailed with
Klenow fragment (Exo). Bar codes containing either 3 or 6 nucleotide
identifiers were ligated onto the fragments with T4 DNA ligase. The liga-
tion products were size selected using AMPure XP beads (Agencourt,
Beverly, MA) by adding 0.8 beads, collecting the supernatant, adding
1.6 beads, discarding the supernatant, and eluting in double-distilled
water (ddH2O). Size selection with beads replaced purification using the
MinElute 96 UF system at this stage. The size-selected products were
amplified using Illumina PE PCR primers and PfuUltra II HotStart high-
fidelity polymerase with the following cycles: 95°C for 2 min; 12 cycles of
95°C for 20 s, 60°C for 20 s, and 72°C for 45 s; and finally 72°C for 10min.
The amplified products were purified, quantified on a NanoDrop 2000
spectrophotometer, combined into libraries, and sequenced on the Illu-
mina HiSeq 2000 platform to generate 100 nucleotide reads. All libraries
contained a control RNA product that was used for sequencing error
analysis (described below).
Bioinformatics analysis. Sequence analysis of IAV populations could
in theory be challenging with short-read sequencing. The high diversity of
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the viral population could lead to incorrect or poor mapping of short
reads with limited homology to a reference genome. Several publicly
available alignment programs were evaluated for the ability to map reads
from IAV populations. BLAST alignment was found to generate the high-
estmapping qualitywith the highest proportion ofmapped reads from the
data. The BLAST algorithm was integrated into an analysis pipeline to
trim and bin the raw read data based on bar codes, align them to the
appropriate reference genome, and obtain as output both the level of
nucleotide variability and the level of amino acid variability within the
viral population. To streamline the processing of large numbers of IAV
samples, a structured query language (SQL) databasewith aWeb interface
has been developed, integrating sample growth conditions withDNAbar-
coding information. The database was directly accessed using the analysis
pipeline, eliminating the potential for human error in correlating experi-
mental conditions with large-scale IAV genomic data.
Short reads from the Illumina platformwere filtered for quality scores
of 20 throughout the read and were aligned to the strain’s reference
genome using BLAST. More than 95% of the selected reads could be
mapped to the IAV reference genome obtained fromGenBank (accession
numbers CY030232, CY031391, CY058484 to CY058486, CY058488,
CY058489, and CY058491). Only alignments longer than 80 nucleotides
were retained. The median sequencing depth was 34,650. Amino acid
frequencies were calculated after alignment of translated reads to the cor-
responding positions in the reference proteins. We confirmed that nucle-
otide and amino acid frequencies were identical between passages. Un-
folded SNP frequencies were generated using the IAV reference genome
and were used for the population genetics analyses; the amino acid fre-
quencies were used for the structural analysis. The sequencing data
sets generated in this study are available at http://bib.umassmed.edu
/influenza.
Sequencing error analysis. Sequence errors can be introduced either
at the sample-processing (PCR) stage, during amplification, or during
sequencing by synthesis. Plasmids encoding the full-length segment 6
(NA) from A/Brisbane/59/2007 or a region of human cytomegalovirus
(HCMV)with a length andGCcontent similar to those of theNA segment
were created. RNA was generated from these plasmids using T7 RNA
polymerase. The RNA pools were then introduced into the sample-pro-
cessing pipeline and were processed and sequenced as controls in a man-
ner identical to that for viral samples. All sequencing runs included the
error constructs to account for any run-to-run variation in error rates.
From these data, the level of error introduced from both sample processing
and sequencing was estimated. Briefly, we calculated the percentage of
nonreference nucleotides in all reads that were mapped to the control se-
quence. The cumulative probability of these nonreference nucleotides indi-
cated that the 95% upper confidence limit of the error rate was 0 to 0.17%.
Therefore, in order to confidently identify low-frequency variants, we dis-
carded all variants that occurred at a frequency of 0.17% or less (see Fig. 2A).
Population genetic analysis. Under a standard single-locus popula-
tion genetic model, the expected change in gene frequency per generation
owing to selection was described by Wright (15). Assuming a constant
population size, it is thus conceivable to directly estimate the selection
coefficients (s) by solving the equation xn  1	 xn (1 s)

t, where xn
and xn  1 are the allele frequencies at passages n and n 1, respectively,
and
t is the number of generations between passages n and n 1. In this
way, s values permutation were inferred from the derived allele frequency
for passages 4 to 9 (P4 to P9) in experiment 1 (andP4 to P12 in experiment
2) in both drug-treated and untreated samples.
Structural analysis. The selection coefficients (described above) were
averaged across replicates (experiments 1 and 2) for each nucleotide. Us-
ing PFAAT (16), the maximum values for the three positions within each
codon were loaded as residue annotations and were mapped to a related
NA structure (Protein Data Bank [PDB] code 3CL0). The selection coef-
ficients were converted to a color spectrum, mapped to the structure, and
visualized in PyMOL.
RESULTS
To delineate the genetic mechanisms that contribute to drug re-
sistance, IAV strain A/Brisbane/59/2007 (H1N1) was subjected to
progressively increasing concentrations of oseltamivir, and the
whole-genome sequence was analyzed over 13 serial passages.
Two evolutionary trajectories for A/Brisbane/59/2007 in MDCK
cells, one in the presence and one in the absence of oseltamivir, are
summarized in Fig. 1. IAV from chicken eggs was propagated in
MDCK cells for 3 passages (passages 1 to 3 [P1 to P3]) to establish
a viral stock for parallel trajectories in the presence or absence of
drug. For the first experiment (Fig. 1A), the virus was passaged 10
additional times in the presence of escalating concentrations of
FIG 1 Experimental trajectories. (A) A/Brisbane/59/2007 (H1N1) was serially passaged in MDCK cells 13 times in the presence of escalating micromolar
concentrations of oseltamivir (open boxes) or no drug (shaded boxes). (B) In a second experiment, A/Brisbane/59/2007 (H1N1) was subjected to similar growth
conditions. Additionally, oseltamivir was withdrawn after passage 10 (P10) and P13, and higher concentrations of oseltamivir were used from P14 to P18. (C)
Viral quantities were compared for no-drug versus oseltamivir-treated samples from experiment 1. Horizontal bars indicate the average values for samples. No
significant differences are observed between input (P, 0.75 by the Mann-Whitney U test) or output (P, 0.28 by the Mann-Whitney U test) copies. (D) Viral
amplification was compared for no-drug samples and oseltamivir-treated samples; again, no significant difference is observed (P, 0.99 by the Mann-Whitney
test).
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oseltamivir, starting with 1 the ED50 (0.1M) at P4. By P13, the
evolved virus was able to tolerate a concentration of oseltamivir
256-fold higher than the ED50. In the second experiment (Fig. 1B),
conditions were expanded to include further escalation of the os-
eltamivir concentration, as well as drug withdrawal beyond P10
and P13. The MOI for each passage was variable. Input virus and
output virus were subsequently quantified for all samples. The aver-
age amounts of input virus in thepresence andabsenceof oseltamivir
were similar (Fig. 1C).No significantdifferenceswereobserved in the
amounts of output virus collected (Fig. 1D). Hence, oseltamivir had
no overall impact on viral amplification.
InfluenzaAvirus genome sequencediversitywith orwithout
oseltamivir. To initially characterize the populations, the distri-
butions of SNP frequencies were analyzed. Several hundred sites
out of 13,500 total nucleotide positions were polymorphic at fre-
quencies above the error frequency cutoff (defined as 0.17%)
(Fig. 2A and Table 1). Yet the majority of SNPs were present at
extremely low frequencies. Figure 2B shows the SNP minor allele
frequency spectra for A/Brisbane/59/2007 at P4 and P13 without
oseltamivir in experiment 1: only a small number of minor alleles
had an increased frequency in the population. Figure 2C shows the
minor allele frequency spectra for A/Brisbane/59/2007 at P13with
oseltamivir in the same experiment. The striking similarity of the
frequency spectra suggests that the selective pressure induced by
oseltamivir does not cause genomewide alterations in levels of
variation. Table 1 shows the numbers of sites in the IAV genome
where theminor alleles were present at frequencies exceeding var-
ious thresholds, ranging from 0.17% (sequencing noise level) to
90% (nearly complete fixation of amutation), for P4 and P13with
and without oseltamivir in the two experiments. Fewer than 100
sites, or 0.7% of the genome, showed appreciable variation (fre-
quency of minor allele,2% in the population) during the exper-
iment, demonstrating that the A/Brisbane/59/2007 influenza vi-
rus genome sequence is strongly constrained. For example, the
numbers of sites with variation of5%at P4 andP13were only 35
and 42, respectively, in experiment 1 without the drug. These
numbers reflect a strong degree of conservation of the influenza
virus genome, suggesting that only a small number of sites expe-
rience appreciable variation during the serial passages.
To further characterize the influence of oseltamivir on IAV
genetic variation, population-level nucleotide diversity was calcu-
lated either for the whole genome (Fig. 3A) or for segment 6 (NA)
alone (Fig. 3B). Nucleotide diversity is an estimate of the average
pairwise percentage of difference between any sequences in a pop-
ulation. Nucleotide diversity increased slowly with serial passag-
ing in the A/Brisbane/59/2007 populations. Because strong selec-
tion is expected to reduce variation, attention was given to the
diversity of the oseltamivir-treated populations after the intro-
duction of drug at P4. The diversity of segment 6 (NA) alone
accounted for approximately half of the average genomewide di-
versity. However, the addition of oseltamivir at P4 seemed to have
little effect on IAV population diversity, whether analyzed as a
genomewide average (Fig. 3A) or in segment 6 (NA) alone (Fig.
3B). In contrast, the degree of viral amplification appeared to have
a considerable impact on nucleotide diversity. We observed that
samples with smaller amounts of input virus and a greater degree
of viral amplification had higher nucleotide diversity (Fig. 3C),
showing that the level of replication in each passage is a stronger
predictor of population diversity than the presence or absence of
drug. Strong selection acting on one population is also expected to
increase the rate of differentiation between two isolated popula-
tions. FST, a metric of population differentiation (17, 18), was
estimated between all samples of this study for each passage. The
population differentiation between drug-treated and untreated
controls was similar to that between two untreated populations
FIG 2 (A) Analysis of error frequency distribution. RNA error controls were
processed and sequenced in a manner identical to that for viral population
samples. These data were used to apply a filtering threshold to the experimen-
tal sequence data. The distribution of mutations in the error control data was
highly skewed to very low frequencies. By filtering data to remove all variation
of0.17%,95% of errors could be removed (arrow), allowing for SNPs to
be called in the population with high confidence. (B) Allele frequency spec-
trum of A/Brisbane/59/2007. Only a very small number of sites in the 13.5-kb
IAV genome exhibited polymorphisms or changes during serial passages in the
absence of oseltamivir. P4 (no drug) is designated by red columns and P13 (no
drug) by black columns. (C) Serial passaging with increasing doses of oselta-
mivir did not increase the sequence diversity of influenza virus. Bars outlined
in red, P4 (no drug); bars outlined in black, P13 (with oseltamivir). Data for
experiment 1 are shown; data for experiment 2 are similar.
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from experiments 1 and 2 (Fig. 3D). These data suggest that osel-
tamivir treatment does not cause a genomewide differentiation of
IAV populations.
Population dynamics of oseltamivir resistance in A/Bris-
bane/59/2007. Changes in the frequency of individual SNPs were
analyzed as a function of passage number. In all experiments and
passages, 50% of SNPs were present at low frequencies (0.25%)
(Fig. 2 and 4). For each experiment, a greater number of SNPs
fixed in the trajectories with oseltamivir than in the trajectories
with no drug. The most striking effect of the drug was observed in
experiment 1, in which sharp rises in the frequencies of four SNPs,
located in segment 4 (hemagglutinin [HA]) and segment 6 (NA),
were observed beginning at P6 (Fig. 4). Yet in experiment 2, the
overall patterns in the presence and absence of the drug were sim-
ilar. In total, the frequency changes for the majority of SNPs in
both experiments did not appear to be altered by the presence of
oseltamivir.
Analysis of the changes in the frequencies of individual SNPs
showed that the known resistance mutation H274Y (2) was the
only SNP that fixed in the presence of oseltamivir in both experi-
TABLE 1 Numbers of sites where SNP frequencies exceed various
thresholdsa
Threshold
(%)
No. of sites where the SNPb frequency exceeds the threshold
Expt 1 Expt 2
No drug Oseltamivir No drug Oseltamivir
P4 P13 P4 P13 P4 P13 P4 P13
0.17 950 1,665 637 1,825 4,134 1,867 3,528 1,698
0.5 358 353 157 557 728 769 700 543
1 172 157 72 206 129 327 180 227
2 76 75 39 83 52 98 114 84
5 35 42 28 37 38 32 38 50
10 22 30 23 27 28 25 27 38
25 14 21 13 21 20 18 21 25
50 13 17 13 20 14 16 14 19
90 12 14 13 15 12 15 13 17
a From 0.17% (sequencing error limit) to 90% (fixation).
b SNP refers to sequence variation with respect to the GenBank reference sequence.
FIG 3 IAV population diversity and divergence in the presence and absence of oseltamivir. The nucleotide diversity of IAV populations was measured for each
passage of in vitro growth. Population divergence wasmeasured by comparing two populations at the same passage using the FST statistic, a metric of population
differentiation. (A) The presence of oseltamivir did not cause a significant change in the amount of variation in the total population. (B)Oseltamivir did not cause
changes in variation in segment 6 (neuraminidase [NA]). (C)Nucleotide diversity was influenced by the amount of input virus and by fold amplification. Trends
are shownby the dashed lines.R2 (Pearson correlation), 0.49 for input virus versus nucleotide diversity and 0.46 for fold amplification versus nucleotide diversity.
Data from experiment 1 are shown. (D) Two populations grownwith andwithout oseltamivir were nomore divergent than two populations grownwithout drug
from the two experiments.
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ments 1 and 2. Remarkably, before the introduction of the drug,
the maximum frequency of the H274Y mutation was 0.085%, be-
low the accurate detection limit of 0.17% (Fig. 5). Therefore, the
H274Y mutation either occurred at extremely low frequencies or
was a de novomutation that arose during the experimental trajec-
tory. The H274Y mutation occurred via a single nucleotide sub-
stitution, C822T.
These data suggest that positive selection causes a sharp rise in
the frequency of the H274Y mutation and possibly others across
the genome. The presence of oseltamivir may have caused a
change in the selective environment, altering the fitness of SNPs
across the genome. To test this hypothesis, selection coefficients
were calculated using time-sampled changes in SNP frequencies
(15). Selection coefficients quantify the fitness advantage or dis-
advantage of a SNP. Values can range from negative for deleteri-
ous SNPs to zero for neutral SNPs and positive for beneficial
SNPs. Oseltamivir did not cause a significant skewing in the
genomewide distributions of selection coefficients in either exper-
iment (Fig. 6). These results suggest that the selective environment
at the genomic level is not altered by oseltamivir. However, a fine-
scale analysis of selection coefficients for all SNPs of segment 6
(NA) showed that the strength and targets of positive selection
were altered in the presence of oseltamivir. The H274Y mutation
was shown to be the most strongly beneficial (Fig. 7), although
there were additionally several low-frequency mutations (G193R,
E227D, K248E, and P326T) near the oseltamivir binding site with
positive selection coefficients. E227D had positive selection coef-
ficients both in the presence and in the absence of drug and thus
was not specific for passage with oseltamivir. Notably, the fre-
quency of the K248E mutation, which is adjacent to H274Y, in-
creased to 19% in the second experiment (P12). As the more ben-
eficial H274Ymutation approached 100% fixation (P13 onward),
the frequency of the K248E mutation was reduced accordingly to
less than 1% in the population. The frequency of the G193R mu-
tation was less than 2%, and the other twomutations (E227D and
P326T) occurred at low frequencies in both the presence and the
absence of drug. Taken together, these results demonstrate that
the H274Y mutation is the primary target of selection in NA and
that the fixation of H274Y in the presence of oseltamivir super-
sedes other potential targets of selection (e.g., K248E).
TheH274Ymutation is neutral in the absence of oseltamivir.
To assess the fitness of the H274Y mutation in the absence of
drug, oseltamivir was withdrawn at key stages in experiment 2.
Following P13, where the frequency of H274Y was 95%, two
parallel trajectories were continued either in the presence or in
the absence of drug (Fig. 1B). Oseltamivir was either continued
at escalating concentrations or withdrawn for five additional
passages (P14 to P18). The frequency of H274Y fixed to 99% by
FIG 4 SNP frequency changes during in vitro growth with or without oseltamivir. The frequencies of all SNPs across the IAV genome were tracked for 13 (A and
B) or 18 (C and D) passages. The presence of oseltamivir caused an increase in the number of SNPs that fixed during passaging. The effect of oseltamivir was
especially pronounced in experiment 1, where a sudden increase in the frequency of a cluster of SNPs can be observed beginning at P6. However, the majority of
SNP frequency changes were not affected by the presence of oseltamivir.
FIG 5 Frequency of the H274Y mutation versus the passage number in
A/Brisbane/59/2007 grown in MDCK cells in the presence or absence of osel-
tamivir. At oseltamivir concentrations of 1 M, the known resistance mu-
tationH274Y emerged and fixed in the population in both experiment 1 (filled
triangles) and experiment 2 (filled circles). Prior to drug treatment, the fre-
quency of H274Y in the population was below 0.1%. The frequency of H274Y
was below 0.1% in the absence of oseltamivir in both experiments (gray lines).
Oseltamivir was added at P4 and beyond; the concentration (along the right y
axis) is indicated by the heavy black line.
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P17 regardless of the presence (Fig. 8, filled triangles) or ab-
sence (Fig. 8, open circles) of oseltamivir. Similarly, oseltamivir
was withdrawn following P10, where the frequency of H274Y
was 23%. Despite the withdrawal of oseltamivir for six addi-
tional passages (P11 to P16), the frequency of the mutation was
maintained at comparable levels (30 to 40%) and appeared to
be governed by genetic drift (Fig. 8, open triangles). Collec-
tively, these results demonstrate that the H274Y mutation is
likely neutral in the absence of drug during serial passaging of
A/Brisbane/59/2007 in MDCK cells.
FIG 6 Genomewide distribution of selection coefficients. Selection coefficients for all SNPs across the genome were calculated using time-sampled changes in
frequency. The distributions were centered on an s of zero, suggesting that most SNPs are neutral and are subject to genetic drift. Further, growth in oseltamivir
had little effect on the distribution, suggesting that the genomewide selective environment is not altered by the presence of the drug.
FIG 7 Selection coefficients for neuraminidase in A/Brisbane/59/2007. Selection coefficients were calculated for the periods corresponding to the development
of drug resistance (P4 onward) with no drug (A) and with increasing concentrations of oseltamivir (B). Data were compiled from experiments 1 and 2. The
selection coefficientsweremapped to the crystal structure of neuraminidase in complexwith oseltamivir (PDB3CL0). TheH274Y resistancemutation is themost
beneficial mutation in the population. The K248Emutation is adjacent to H274Y and is a target of positive selection with oseltamivir in one of two experiments.
The spectrum of colors ranges from the lowest-ranked (violet) to the highest-ranked (red) selection coefficients.
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IC50 measurements correlate with the frequency of the osel-
tamivir resistance mutation. To assess if oseltamivir resistance
correlated with the relative frequency of the H274Y mutation in
strain A/Brisbane/59/2007, enzyme inhibition studies were per-
formed on select samples. The 50% enzyme-inhibitory concentra-
tions (IC50) of oseltamivir were assessed on samples without osel-
tamivir in the supernatant to provide for accurate measurements.
Successful replication of resistant viruses in the presence of in-
creasing concentrations of oseltamivir was accompanied by the
increases in the enzymatic IC50 of oseltamivir for neuraminidase
(Fig. 8). At P13 and beyond, the H274Ymutation was present at a
frequency of99%. The mean IC50 for these samples was 49.8
6.8 nM (n 	 3). This was significantly higher than the IC50 for
neuraminidase in the oseltamivir-sensitive control samples (0.10
0.01 nM [n 	 6]; P, 0.0001 by Student’s unpaired t test), in
which the H274Y mutation was below the detection limit, and
indicates oseltamivir resistance at P13. Following oseltamivir
withdrawal at P10, the frequency of H274Y drifted between 30%
and 40%. The correspondingmean IC50 was 0.17 0.02 nM (n	
3), also significantly higher than that for oseltamivir-sensitive
control samples (0.10  0.01 nM) (P, 0.01 by Student’s un-
paired t test). Therefore, the presence of the H274Y mutation in
the viral population, either at a low or at a high frequency, led to
measurable changes in the neuraminidase inhibition assay results.
DISCUSSION
Accurately unraveling the evolutionary changes of a viral popula-
tion in response to a selective pressure was previously elusive. In
the past, information about influenza virus sequence diversity was
typically inferred from large sets of consensus sequences deter-
mined from clinical isolates (19), and it was difficult to resolve the
genetic structure of well-defined individual IAV populations. In
the current study, we have used high-throughput sequencing to
closely monitor the population genetics of IAV strain A/Brisbane/
59/2007 in response to oseltamivir. Surprisingly, the genomewide
effects of oseltamivir were minimal, although high-resolution
analysis revealed the subtleties associated with drug resistance.
IAV can rapidly evolve and adapt to drugs or changes in the
environment through rapidmutation and replication, strong nat-
ural selection, and genome segment reassortment. By subjecting
A/Brisbane/59/2007 to oseltamivir under controlled conditions,
we were able to track the frequency of resistantmutants over time.
Initially, mutants occurred at exceptionally low frequencies
(0.085%), and they rose to fixation within only a few serial pas-
sages in each case. Since the mutation rate of influenza virus in
vitro is between 106 and 105 mutation per site per infectious
cycle (20), the resistance mutation may have developed de novo.
Strong population bottlenecks during serial passaging at a low
MOI would make it unlikely for the preexisting resistance muta-
tion to remain at such a low frequency (104) over multiple
passages prior to the introduction of the drug. We also expect the
evolutionary trajectories to be similar in individual infected hu-
mans, since the H274Y resistance mutation was observed at low
frequencies (3.7%) in influenza virus samples isolated from a
single patient prior to oseltamivir therapy (21, 22). Our results
show that the development of oseltamivir resistance in A/Bris-
bane/59/2007 is not associated with large changes in population
sequence diversity or divergence. Further, the genomewide dis-
tribution of selection coefficients is not significantly altered by
the presence of the drug, suggesting that the overall selective
environments for A/Brisbane/59/2007 in MDCK cells are sim-
ilar in the presence and absence of drug. If the development of
resistance were associatedwith genomewide changes in constraint
or increased strength of epistatic interactions, one would expect
genomewide alteration of the distribution of selection coefficients
due to alterations of the fitness landscape (23). Given these results
and the fact that the H274Y mutation arises from a single nucleo-
tide change, not much may hinder the conversion of a drug-sen-
sitive population to drug resistance. These data support the ob-
served rise in the occurrence of oseltamivir resistance in seasonal
H1N1 isolates from 2007 to 2009 (5). Others have found epistatic
interactions between the H274Ymutation and othermutations in
NA: the fitness of the resistant virus is increased by the presence of
the V234M and R222Q mutations (24). Because these mutations
are encoded by strain A/Brisbane/59/2007 as well as by many re-
cent H1N1 isolates (24), our data show how current H1N1 strains
are “primed” for the development of resistance with little imped-
iment at the genomewide or population level. The absence of a
fitness penalty for the H274Y mutation in quasispecies popula-
tions may contribute to its prevalence in humans. An interesting
question to address using our system is whether other resistance
mutations in the neuraminidase gene are stable or would disap-
pear from the population in the absence of permissive secondary
mutations. Future drug design should be influenced not only by
structural considerations, as was the case for oseltamivir (25, 26),
but also by evolutionary information, to reduce the likelihood of
resistance.
Surprisingly, variation in the influenza virus genome sequence
was constrained. Out of the entire 13.5-kb IAV genome, signifi-
FIG 8 Impact of oseltamivir withdrawal on H274Y frequency in A/Brisbane/
59/2007 and correlation with IC50s for neuraminidase. Shown is the frequency
of the H274Y mutation for select samples in the second experimental trajec-
tory with A/Brisbane/59/2007. After P13, the removal of the drug has no effect
on H274Y frequency (open circles). The removal of the drug at P10, before
H274Y reached fixation, did not lead to a significant change in H274Y fre-
quency (open triangles). Mean oseltamivir IC50s for influenza virus samples
beyondP13 andP10 versus those for control virus (wild type) are given. Values
were determined using a chemiluminescent neuraminidase activity inhibition
assay. For samples inwhichH274Y remains fixed in the population (open circles),
the IC50 is100-fold that for the wild-type control virus (means, 49.8 6.8 nM
versus 0.10 0.01 nM; P,0.001 by Student’s t test). For samples in which the
frequency of H274Y is 40% in the population (open triangles), the IC50 is
slightly but significantly greater than that for the wild-type control virus
(means, 0.17 0.02 nM versus 0.10 0.01 nM; P,0.001 by Student’s t test).
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cant variation developed in only about 100 sites (0.7%) for the
A/Brisbane/59/2007 experiments over 13 passages (Table 1). Fur-
ther, the nucleotide diversity of the genome was significantly less
than that of other RNA viruses, such as hepatitis C virus (27),
although the latter was sampled from in vivo populations. Such a
strong degree of conservation in a rapidlymutating RNAvirus can
be due to a combination of factors, including constraints on pro-
tein function, correct folding and packaging of the RNA segments,
and maintenance of appropriate codon bias. In an initial effort to
better understand these events, we investigated how influenza vi-
rus genome packaging can be impacted by factors such as segment
self-repulsion (28), highlighting the importance of packaging sig-
nals for viral replication. Further understanding of the fitness con-
sequences of SNPs across the genome will help elucidate the
mechanism underlying the conservation.
Several neuraminidase inhibitor resistance mutations have
been reported in the literature (29). However, when A/Brisbane/
59/2007 was treated with oseltamivir in two separate experiments,
the H274Y mutation fixed rapidly in both populations. Although
theH274Ymutation was the primary target of selection in A/Bris-
bane/59/2007, the neighboring K248E mutation was observed at
relatively high frequencies in one of the experiments (19% inP12).
The K248E mutation was also identified as a target of positive
selection during this period. However, as the more beneficial
H274Y mutation approached fixation (P13 onward), there was a
corresponding reduction in the frequency of the K248E mutation
in the population (below 1%), highlighting the importance of
competition during viral evolution.
Our enzyme inhibition studies demonstrated a relationship
between oseltamivir resistance and the relative frequency of the
H274Ymutation in the population. In the presence of oseltamivir,
the mutation provides an unequivocal selective advantage that
leads to its rapid fixation, indicated by the reproducibly positive
selection coefficients for this mutation. However, as shown in the
enzymatic assays, the full functional advantage of the mutation is
not apparent until it is present at very high frequencies.When this
mutation was present in approximately one-third of the popula-
tion, the enzymatic activity was slightly, though significantly,
higher than that of a control population without the mutation.
These data provide a functional basis for the rapid fixation of the
mutation in the presence of oseltamivir during in vitro growth in
this study, or during in vivo replication, as observed by others (21).
Collectively, temporal high-throughput sequencing studies for
oseltamivir provide a framework for analysis of the evolution of
IAV under additional selective pressures, such as novel antiviral
agents and antiviral immunity. Such analyses will be crucial for
understanding the evolution of drug resistance and for improving
vaccine design. Future temporal high-throughput sequencing
studies of influenza virus will help address many of the challenges
posed by this pathogen and will bring us closer to relevant, robust
in vitromodeling of influenza virus evolution.
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